Ovarian Cancer

>

Latest News

Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months in patients with platinum-resistant ovarian cancer.
FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer

July 15th 2025

Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months, respectively, in patients with platinum-resistant ovarian cancer.

Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype
Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype

July 14th 2025

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.
PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer

June 4th 2025

Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.
Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer

June 2nd 2025

Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer
Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer

June 2nd 2025

Latest CME Events & Activities

More News